Axinn Patent Attorneys Talk ACA Pushback and the BPCIA
May 4, 2020
The Center for Biosimilars
On May 4, Axinn partner Ted Mathias participated in a video interview with The Center for Biosimilars. He discussed the overall pushback to the Affordable Care Act (ACA) and what that means for the Biologics Price Competition and Innovation Act (BPCIA).
Click to access part 1, part 2, and part 3 of the interview.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI 22nd Annual Paragraph IV Conference
Speaking Engagement
Intellectual Property
Informa 35th Annual Advanced EU London Conference
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2026
Sponsorship
Antitrust
Kenina Lee Selected as a Member of Law360’s 2026 Competition Editorial Advisory Board
Awards & Recognitions
Antitrust
Axinn Associates at the Antitrust Spring Meeting: You Get a Deal, You Get a Deal—A Deal in Every Environment
Axinn Viewpoints
Antitrust
Axinn Associates at the Spring Meeting: Trends in Federal Antitrust Enforcement and Policy
Axinn Viewpoints
Antitrust
Axinn Associates at the Antitrust Spring Meeting: Cartel Enforcement Trends and Developments
Axinn Viewpoints
Antitrust
Axinn Associates at the Antitrust Spring Meeting: Tech-Related Enforcement
Axinn Viewpoints
Antitrust
Leadership Across the Generations: A Conversation Between Mentor and Mentee
Byline Articles
Antitrust
Ultramarathons Make Me A Better Lawyer
Byline Articles
Antitrust
